As a targeted drug for the treatment of basal cell carcinoma, the usage and dosage of Erivedge should strictly follow the weight standard, and the use of Erivedge in special populations should focus on reproductive toxicity and liver and kidney function effects. The following provides a detailed explanation from two aspects: standard dosing regimen and adjustments for special populations.

1. Standard usage and dosage

(1) Administration method: Oral administration, once daily, recommended to be taken at a fixed time. Capsules should be swallowed whole and should not be opened or chewed.

(2) Dose calculation: The recommended dose for patients weighing ≥ 50kg is 150mg/day; For individuals weighing less than 50kg, the daily dose is calculated at 3mg/kg.

(3) Duration of treatment: Continue treatment until disease progression or intolerable toxicity occurs, with an average medication duration of 10.2 months in clinical studies.

2. Medication for special populations

(1) Reproductive related population

Pregnant women: Based on animal teratogenic data, it is absolutely prohibited during pregnancy. Women of childbearing age need to confirm a negative pregnancy test before taking medication, and efficient contraception should be used during treatment and 24 months after the last dose.

Breastfeeding period: Medication may be secreted into breast milk, and breastfeeding should be stopped during treatment and 24 months after discontinuation of medication.

(2) Individuals with abnormal liver function

Child Pugh Grade A: Requires a 25% reduction in usage, recommended to adjust to 112.5mg/day (for standard weight individuals).

Child Pugh B/C grade: Prohibited for use as significant inhibition of drug metabolism may result in severe toxicity.

(3) Individuals with renal insufficiency

Mild to moderate impairment (eGFR30-89ml/min): No dose adjustment is required, but creatinine monitoring needs to be strengthened.

Severe damage (eGFR<30ml/min): Lack of safety data, not recommended for use.

(4) Elderly patients

Patients aged 65 and above do not require routine dose adjustments, but caution should be exercised when concomitant medication is used to avoid the risk of QT interval prolongation. Baseline and monthly electrocardiogram monitoring are recommended.